Event-related potentials (ERPs) in ecstasy (MDMA) users during a visual oddball task

Ecstasy is the common name for a drug mainly containing a substance identified as 3,4-methylenedioxymethamphetamine (MDMA). It has become popular with participants in "raves", because it enhances energy, endurance and sexual arousal, together with the widespread belief that MDMA is a safe drug [Byard, R.W., Gilbert, J., James, R., Lokan, R.J., 1998. Amphetamine derivative fatalities in South Australia. Is "ecstasy" the culprit? Am. J. Forensic Med. Pathol. 19, 261-265]. However, it is suggested that this drug causes a neurotoxicity to the serotonergic system that could lead to permanent physical and cognitive problems. In order to investigate this issue, and during an ERP recording with 32 channels, we used a visual oddball design, in which subjects (14 MDMA abusers and 14 paired normal controls) saw frequent stimuli (neutral faces) while they had to detect as quickly as possible rare stimuli with happy or fearful expression. At a behavioral level, MDMA users imply longer latencies than normal controls to detect rare stimuli. At the neurophysiological level, ERP data suggest as main result that the N200 component, which is involved in attention orienting associated to the detection of stimulus novelty (e.g. [Campanella, S., Gaspard, C., Debatisse, D., Bruyer, R., Crommelinck, M., Guerit, J.M., 2002. Discrimination of emotional facial expression in a visual oddball task: an ERP study. Biol. Psychol. 59, 171-186]), shows shorter latencies for fearful rare stimuli (as compared to happy ones), but only for normal controls. This absence of delay was interpreted as an attentional deficit due to MDMA consumption.

[1]  W. van den Brink,et al.  Cortical serotonin transporter density and verbal memory in individuals who stopped using 3,4-methylenedioxymethamphetamine (MDMA or "ecstasy"): preliminary findings. , 2001, Archives of general psychiatry.

[2]  R. Croft,et al.  Chronic MDMA (ecstasy) use, cognition and mood , 2004, Psychopharmacology.

[3]  T. Allison,et al.  Electrophysiological Studies of Face Perception in Humans , 1996, Journal of Cognitive Neuroscience.

[4]  S. Kish.  How strong is the evidence that brain serotonin neurons are damaged in human users of ecstasy? , 2002, Pharmacology Biochemistry and Behavior.

[5]  J. Krystal,et al.  Chronic 3,4-methylenedioxymethamphetamine (MDMA) use: effects on mood and neuropsychological function? , 1992, The American journal of drug and alcohol abuse.

[6]  J S Fowler,et al.  Association of dopamine transporter reduction with psychomotor impairment in methamphetamine abusers. , 2001, The American journal of psychiatry.

[7]  S. Rauch,et al.  Masked Presentations of Emotional Facial Expressions Modulate Amygdala Activity without Explicit Knowledge , 1998, The Journal of Neuroscience.

[8]  B. Rossion,et al.  Right N170 modulation in a face discrimination task: an account for categorical perception of familiar faces. , 2000, Psychophysiology.

[9]  F. Vollenweider,et al.  Gender differences in the subjective effects of MDMA , 2001, Psychopharmacology.

[10]  J. Brodkin,et al.  Effect of acute monoamine depletion on 3,4-methylenedioxymethamphetamine-induced neurotoxicity , 1993, Pharmacology Biochemistry and Behavior.

[11]  J. Pernier,et al.  ERP Manifestations of Processing Printed Words at Different Psycholinguistic Levels: Time Course and Scalp Distribution , 1999, Journal of Cognitive Neuroscience.

[12]  F. Benazzi,et al.  Psychiatric illness associated with "ecstasy" , 1991, The Lancet.

[13]  John E. Perez,et al.  Nonverbal Social Skills and Psychopathology , 2003 .

[14]  M. Olff,et al.  Cortisol, Learning, Memory, and Attention in Relation to Smaller Hippocampal Volume in Police Officers with Posttraumatic Stress Disorder , 2006, Biological Psychiatry.

[15]  C. Lyketsos,et al.  Cannabis use and cognitive decline in persons under 65 years of age. , 1999, American journal of epidemiology.

[16]  R. Dolan,et al.  Conscious and unconscious emotional learning in the human amygdala , 1998, Nature.

[17]  E. Halgren,et al.  Spatio-temporal stages in face and word processing. 2. Depth-recorded potentials in the human frontal and Rolandic cortices , 1994, Journal of Physiology-Paris.

[18]  Z. Szabo,et al.  Positron emission tomographic evidence of toxic effect of MDMA (“Ecstasy”) on brain serotonin neurons in human beings , 1998, The Lancet.

[19]  R. Buchert,et al.  Long-term effects of ‘ecstasy’ abuse on the human brain studied by FDG PET , 2001, Nuclear medicine communications.

[20]  B. Sahakian,et al.  Neuropsychological evidence of a relatively selective profile of temporal dysfunction in drug-free MDMA ("ecstasy") polydrug users , 2002, Psychopharmacology.

[21]  U. McCann,et al.  Lasting neuropsychiatric sequelae of (+-)methylenedioxymethamphetamine ('ecstasy') in recreational users. , 1991, Journal of clinical psychopharmacology.

[22]  M. Rugg,et al.  Electrophysiology of Mind: Event-Related Brain Potentials and Cognition , 1995 .

[23]  G. Gerra,et al.  Serotonergic function after (±)3,4‐methylene-dioxymethamphetarnine (‘Ecstasy’) in humans , 1998, International clinical psychopharmacology.

[24]  L. Deouell,et al.  STRUCTURAL ENCODING AND IDENTIFICATION IN FACE PROCESSING: ERP EVIDENCE FOR SEPARATE MECHANISMS , 2000, Cognitive neuropsychology.

[25]  L. Itti,et al.  Effect of ecstasy [3,4-methylenedioxymethamphetamine (MDMA)] on cerebral blood flow: a co-registered SPECT and MRI study , 2000, Psychiatry Research: Neuroimaging.

[26]  Kenneth M. Heilman,et al.  Neuropsychology of human emotion , 1983 .

[27]  Pierre Philippot,et al.  Nonverbal Behavior in Clinical Settings , 2003 .

[28]  T. Dierks,et al.  Cerebral networks linked to the event-related potential P300 , 2003, European Archives of Psychiatry and Clinical Neuroscience.

[29]  E. Gouzoulis-Mayfrank,et al.  Impaired cognitive performance in drug free users of recreational ecstasy (MDMA) , 2000, Journal of neurology, neurosurgery, and psychiatry.

[30]  P. Ekman.  Pictures of Facial Affect , 1976 .

[31]  D. Yurgelun-Todd,et al.  Neuropsychological performance in long-term cannabis users. , 2001, Archives of general psychiatry.

[32]  R Bruyer,et al.  Human gender differences in an emotional visual oddball task: an event-related potentials study , 2004, Neuroscience Letters.

[33]  R. Bost,et al.  'Eve' and 'Ecstasy'. A report of five deaths associated with the use of MDEA and MDMA. , 1987, JAMA.

[34]  Trevor W Robbins,et al.  Investigating the neurocognitive deficits associated with chronic drug misuse , 2001, Current Opinion in Neurobiology.

[35]  S. Campanella,et al.  Categorical Perception of Happiness and Fear Facial Expressions: An ERP Study , 2002, Journal of Cognitive Neuroscience.

[36]  M. Crommelinck,et al.  Discrimination of emotional facial expressions in a visual oddball task: an ERP study , 2002, Biological Psychology.

[37]  R. Buchert,et al.  Ecstasy – long-term effects on the human central nervous system revealed by positron emission tomography , 1999, British Journal of Psychiatry.

[38]  J. V. van Gerven,et al.  Cognitive performance and serotonergic function in users of ecstasy , 2000, Psychopharmacology.

[39]  M. Galloway,et al.  MDMA induced dopamine release in vivo: role of endogenous serotonin , 2005, Journal of Neural Transmission.

[40]  U. Hess,et al.  Impaired emotional facial expression recognition in alcoholics, opiate dependence subjects, methadone maintained subjects and mixed alcohol-opiate antecedents subjects compared with normal controls , 2003, Psychiatry Research.

[41]  D. Perrett,et al.  A differential neural response in the human amygdala to fearful and happy facial expressions , 1996, Nature.

[42]  E. Turillazzi,et al.  Adam (MDMA) and Eve (MDEA) misuse: an immunohistochemical study on three fatal cases. , 1999, Forensic science international.

[43]  R. Byard,et al.  Amphetamine derivative fatalities in South Australia--is "Ecstasy" the culprit? , 1998, The American journal of forensic medicine and pathology.

[44]  H. Altman,et al.  What is the nature of the role of the serotonergic nervous system in learning and memory: Prospects for development of an effective treatment strategy for senile dementia , 1988, Neurobiology of Aging.

[45]  U. McCann,et al.  3,4-Methylenedioxymethamphetamine (MDMA, "Ecstasy"): pharmacology and toxicology in animals and humans. , 1994, Addiction.

[46]  F. Vollenweider,et al.  No Difference in Brain Activation During Cognitive Performance Between Ecstasy (3,4-Methylenedioxymethamphetamine) Users and Control Subjects: A [H215O]-Positron Emission Tomography Study , 2001, Journal of clinical psychopharmacology.

[47]  Pierre Philippot,et al.  The regulation of emotion , 2004 .

[48]  Thomas Babor,et al.  Cognitive functioning of long-term heavy cannabis users seeking treatment. , 2002, JAMA.

[49]  Bruno Rossion,et al.  Early lateralization and orientation tuning for face, word, and object processing in the visual cortex , 2003, NeuroImage.

[50]  R. Knight,et al.  Predictive value of novel stimuli modifies visual event-related potentials and behavior , 2000, Clinical Neurophysiology.

[51]  R. Davidson,et al.  The functional neuroanatomy of emotion and affective style , 1999, Trends in Cognitive Sciences.

[52]  G. Fink,et al.  Neural activation during selective attention to subjective emotional responses , 1997, Neuroreport.

[53]  U. McCann,et al.  MDMA (“Ecstasy”) and panic disorder: Induction by a single dose , 1992, Biological Psychiatry.

[54]  A. Parrott,et al.  Recreational Ecstasy/MDMA, the serotonin syndrome, and serotonergic neurotoxicity , 2002, Pharmacology Biochemistry and Behavior.

[55]  U. McCann,et al.  (±)3,4-Methylenedioxymethamphetamine (‘Ecstasy’)-Induced Serotonin Neurotoxicity: Studies in Animals , 2000, Neuropsychobiology.

[56]  Pierre Philippot,et al.  Cognitive regulation of emotion: Application to clinical disorders. , 2004 .

[57]  R. Buchert,et al.  Specific neurotoxicity of chronic use of ecstasy. , 2002, Toxicology letters.

[58]  S. Luck,et al.  Sources of attention-sensitive visual event-related potentials , 2005, Brain Topography.

[59]  G. Kim,et al.  Dopaminergic influences on the P300 abnormality in Parkinson's disease , 1998, Journal of the Neurological Sciences.

[60]  Karl J. Friston,et al.  Regional cerebral blood flow in depression measured by positron emission tomography: the relationship with clinical dimensions , 1993, Psychological Medicine.

[61]  M. Ansseau,et al.  P300 event-related potential and serotonin-1A activity in depression , 1999, European Psychiatry.

[62]  Ulrich Hegerl,et al.  Neurochemical Substrates and Neuroanatomical Generators of the Event-Related P300 , 1999, Neuropsychobiology.

[63]  G. Rainer,et al.  Cognitive neuroscience: Neural mechanisms for detecting and remembering novel events , 2003, Nature Reviews Neuroscience.

[64]  M. Gazzaniga,et al.  Combined spatial and temporal imaging of brain activity during visual selective attention in humans , 1994, Nature.

[65]  J. Cadet,et al.  Methylenedioxymethamphetamine (MDMA, Ecstasy) neurotoxicity: cellular and molecular mechanisms , 2003, Brain Research Reviews.

[66]  M. Hillbom,et al.  Neurological complications of drug abuse: pathophysiological mechanisms , 2000, European journal of neurology.

[67]  K. Petersen,et al.  Mood, cognition and serotonin transporter availability in current and former ecstasy (MDMA) users , 2003, Psychopharmacology.

[68]  Klaus P. Ebmeier,et al.  Reduced in vivo binding to the serotonin transporter in the cerebral cortex of MDMA (‘ecstasy’) users , 1999, British Journal of Psychiatry.

[69]  B. Price,et al.  Long-term neuropsychiatric consequences of "ecstasy" (MDMA): a review. , 2002, Harvard review of psychiatry.

[70]  D. Jeffreys.  A face-responsive potential recorded from the human scalp , 2004, Experimental Brain Research.

[71]  J. Deakin.  The role of serotonin in panic, anxiety and depression. , 1998, International clinical psychopharmacology.

[72]  B. Rossion,et al.  Task modulation of brain activity related to familiar and unfamiliar face processing: an ERP study , 1999, Clinical Neurophysiology.